Literature DB >> 24279194

Management of amyotrophic lateral sclerosis.

Taha Bali1, Timothy M Miller.   

Abstract

Motor Neuron Diseases (MNDs) are neurological disorders characterized by the selective and progressive degeneration of motor neurons. Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is the most common. ALS causes diffuse muscle weakness and death secondary to respiratory failure. The diagnosis is made clinically, supported by electrodiagnostic testing. Although medications are limited, careful attention to breathing, nutrition, and patient mobility can have a major, positive impact on the course of the disease.

Entities:  

Mesh:

Year:  2013        PMID: 24279194      PMCID: PMC6179867     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  19 in total

1.  Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review).

Authors:  R G Miller; J A Rosenberg; D F Gelinas; H Mitsumoto; D Newman; R Sufit; G D Borasio; W G Bradley; M B Bromberg; B R Brooks; E J Kasarskis; T L Munsat; E A Oppenheimer
Journal:  Muscle Nerve       Date:  1999-08       Impact factor: 3.217

2.  Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial.

Authors:  Stephen C Bourke; Mark Tomlinson; Tim L Williams; Robert E Bullock; Pamela J Shaw; G John Gibson
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

3.  Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis.

Authors:  L Mazzini; T Corrà; M Zaccala; G Mora; M Del Piano; M Galante
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

4.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

Review 5.  Muscle cramps.

Authors:  Timothy M Miller; Robert B Layzer
Journal:  Muscle Nerve       Date:  2005-10       Impact factor: 3.217

6.  Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside.

Authors:  Alan Pestronk; Miguel Chuquilin; Rati Choksi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07       Impact factor: 10.154

7.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

8.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Authors:  B R Brooks; R A Thisted; S H Appel; W G Bradley; R K Olney; J E Berg; L E Pope; R A Smith
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

9.  A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.

Authors:  C E Jackson; J Rosenfeld; D H Moore; W W Bryan; R J Barohn; M Wrench; D Myers; L Heberlin; R King; J Smith; D Gelinas; R G Miller
Journal:  J Neurol Sci       Date:  2001-10-15       Impact factor: 3.181

10.  Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population.

Authors:  A Czaplinski; A A Yen; S H Appel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

View more
  2 in total

1.  GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis.

Authors:  William R Swindell; Krzysztof Bojanowski; Mark S Kindy; Raymond M W Chau; Dorothy Ko
Journal:  Transl Neurodegener       Date:  2018-12-03       Impact factor: 8.014

2.  Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Authors:  Fardin Nabizadeh; Mohammad Balabandian; Amir Mohammad Sharafi; Ali Ghaderi; Mohammad Reza Rostami; Abdorreza Naser Moghadasi
Journal:  Acta Neurol Belg       Date:  2021-07-28       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.